Trial Number

657-26

Participant Age Range

180 Days to 22 Years

Participant Gender

Any

Enrolling Participants

Yes

Overview

“Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis”

Researchers are studying an investigational targeted therapy called tovorafenib (DAY101) for children, adolescents, and young adults with relapsed or refractory Langerhans cell histiocytosis (LCH). LCH is a rare disease in which abnormal immune cells can damage tissues and organs. This Phase 2 study will evaluate how well tovorafenib works, how long responses last, and its safety in patients whose disease has returned or did not respond to previous treatment. Participants will take tovorafenib by mouth once weekly for up to 12 months and will undergo regular exams, blood tests, imaging scans, and follow-up visits.

Provider

Jacqueline N Casillas, MD

Hematology-Oncology - Pediatric, Pediatric Hematology/Oncology
Long Beach, Torrance
View Profile

Location

Miller Children’s & Women’s Hospital

2801 Atlantic Avenue
Long Beach
562-933-5437
Location Details

Related Clinical Trials

Click on the category you are interested in.

Cancer Care Pediatric Care Pediatric Specialty Care Miller Children's & Women's Hospital
Name
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.